

**Methodological note** and the transparency data for payments made by Daiichi Sankyo UK (DSUK) to members of the public, including patients and journalists, in accordance with the ABPI Code of Practice for the Pharmaceutical Industry (the ABPI Code) between 01 January 2023 and 31st December 2023.

- **Payment** means financial support provided by DSUK to a member of the public whom we engage with for services specifically related to healthcare, disease, or medicine.
- **Member of Public** includes but is not limited to, patients, carers, health economists, and journalists who live in the United Kingdom and whom DSUK engages with for services specifically related to healthcare, disease, or medicine.
- **Services** provided by a member of the public can include consultancy, advisory or training roles related to healthcare, disease, or medicine, participating in market research, or speaking engagements. Payments for work to support clinical trials are excluded if they fall within the remit of Research and Development payments as defined in the ABPI code, including consultancy specific to a clinical trial or Data Management Committee service. Such payments are reported on Disclosure UK ([abpi.org.uk](http://abpi.org.uk)).
- **Currency** - disclosures are made in Great British pounds
- **Value Added Tax** - this is not included in the amount disclosed

These figures do not include payments to patient advocates or other individuals who are representatives of Patient Organisations for services provided to DSUK. Instead, these payments are reported as payments to Patient Organisations and can be found in a separate report on <https://www.daiichi-sankyo.co.uk/about-us/who-we-are/disclosure-of-payments/>

This disclosure for members of the public is made on an aggregate basis. It includes the total amount of payments made and the total number of individuals in the report.

# Transfer of Value Disclosure for: Members of the Public, Patients and Journalists

Daiichi Sankyo UK Ltd – 2023

	Total Fees for Contracted Services	Expenses	Number of individuals included in aggregate	Description of Types of Services
<b>Members of the Public</b>	£6,050	n/a	3	Participation in Health Technology Assessment Advisory Board and Speaker services
<b>Patients:</b>	n/a	n/a	n/a	n/a
<b>Journalists:</b>	n/a	n/a	n/a	n/a